Search Results - "Wharton, Sean"

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 by Kushner, Robert F., Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Garvey, W. Timothy, Goldman, Bryan, Lingvay, Ildiko, Thomsen, Mette, Wadden, Thomas A., Wharton, Sean, Wilding, John P.H., Rubino, Domenica

“…Objective The obesity epidemic is a public health concern, warranting further research into pharmacological treatments for weight management (WM) as an adjunct…”
Get full text

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data by Wharton, Sean, Astrup, Arne, Endahl, Lars, Lean, Michael E. J., Satylganova, Altynai, Skovgaard, Dorthe, Wadden, Thomas A., Wilding, John P. H.

“…In the approval process for new weight management therapies, regulators typically require estimates of effect size. Usually, as with other drug evaluations,…”
Get full text

Substantial Changes in Epicardial Fat Thickness After Weight Loss in Severely Obese Subjects by Iacobellis, Gianluca, Singh, Navneet, Wharton, Sean, Sharma, Arya M

“…We sought to evaluate the effect of weight loss on echocardiographic epicardial fat thickness, as index of visceral adiposity, and whether epicardial fat…”
Get full text

Predictors of Weight Loss and Weight Gain in Weight Management Patients during the COVID-19 Pandemic by Kuk, Jennifer L., Christensen, Rebecca A. G., Kamran Samani, Elham, Wharton, Sean

“…Objective. To examine the associations between patient struggles, health, and weight management changes during the COVID-19 pandemic. Methods. 585 patients…”
Get full text

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update by Tobe, Sheldon W., MD MScCH, Stone, James A., MD PhD, Anderson, Todd, MD, Bacon, Simon, PhD, Cheng, Alice Y.Y., MD, Daskalopoulou, Stella S., MD PhD, Ezekowitz, Justin A., MBBCh MSc, Gregoire, Jean C., MD, Gubitz, Gord, MD, Jain, Rahul, MD MScCH, Keshavjee, Karim, MSc MD, Lindsay, Patty, RN PhD, L’Abbe, Mary, PhD, Lau, David C.W., MD PhD, Leiter, Lawrence A., MD, O’Meara, Eileen, MD, Pearson, Glen J., PharmD, Rabi, Doreen M., MD MSc, Sherifali, Diana, RN PhD, Selby, Peter, MBBS MHSc, Tu, Jack V., MD PhD, Wharton, Sean, MD PharmD, Walker, Kimberly M., MPH, Hua-Stewart, Diane, MPH, Liu, Peter P., MD

“…Tobe et al cite that the Canadian Cardiovascular Harmonized National Guideline Endeavor (C-CHANGE) is a nationally endorsed guideline process, targeting…”
Get full text

Current Perspectives on Long-term Obesity Pharmacotherapy by Wharton, Sean, MD, FRCPC, PharmD

“…Abstract Approximately 1 in 4 adult Canadians are obese and, thus, are at an elevated risk for developing type 2 diabetes, cardiovascular disease and other…”
Get full text

Absolute Weight Loss, and Not Weight Loss Rate, Is Associated with Better Improvements in Metabolic Health by Kuk, Jennifer L., Wharton, Sean, Christensen, Rebecca A. G.

“…Objective. To determine if the rate of weight loss (WL) is associated with metabolic changes independent of the absolute WL. Methods. WL and health changes…”
Get full text

Receptivity to Bariatric Surgery in Qualified Patients by Kuk, Jennifer L., Macpherson, Alison, Wharton, Sean, Fung, Michael

“…Objectives. Bariatric surgery has been shown to be an effective intervention for weight loss and diabetes management. Despite this, many patients qualified for…”
Get full text

Edmonton Obesity Staging System Prevalence and Association with Weight Loss in a Publicly Funded Referral-Based Obesity Clinic by Sharma, Arya Mitra, Wharton, Sean, Brown, Ruth E., Canning, Karissa L., Kuk, Jennifer L.

“…Objectives. To determine the distribution of EOSS stages and differences in weight loss achieved according to EOSS stage, in patients attending a…”
Get full text

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada by Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.

“…Summary Objective Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this…”
Get full text

The Association between Antihypertensive Medication Use and Blood Pressure Is Influenced by Obesity by Edgell, Heather, Wharton, Sean, Randhawa, Arshdeep K., Parikh, Jash S., Kuk, Jennifer L.

“…Introduction. One in three US adults is living with obesity or hypertension, and more than 75% of hypertensive individuals are using antihypertensive…”
Get full text

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program by Wharton, Sean, Haase, Christiane L, Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca AG

“…Summary Objective Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients…”
Get full text

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply by Wharton, Sean, Konig, Manige

Get full text

Feasibility of an interdisciplinary program for obesity management in Canada by Wharton, Sean, VanderLelie, Sarah, Sharma, Arya M, Sharma, Saaqshi, Kuk, Jennifer L

“…To assess the feasibility of a medically supervised, publicly funded interdisciplinary program for obesity management in a Canadian setting. Retrospective…”
Get full text

Treating obesity as a chronic disease in Canada: We are not there yet by Wharton, Sean

Get full text

Consistent Reduction of Postprandial Glucagon and Insulin by Lixisenatide in the GetGoal Clinical Trial Program by Wharton, Sean N, Berria, Rachele, Stager, William, Gautier, Jean-Francois, Aronson, Ronnie, Ahrén, Bo

Get full text

Weight Management in Diabetes by Wharton, Sean, MD, FRCPC, PharmD, Sharma, Arya M., MD, PhD, FRCPC, Lau, David C.W., MD, PhD, FRCPC

Get full text

Tirzepatide Once Weekly for the Treatment of Obesity by Jastreboff, Ania M., Aronne, Louis J., Ahmad, Nadia N., Wharton, Sean, Connery, Lisa, Alves, Breno, Kiyosue, Arihiro, Zhang, Shuyu, Liu, Bing, Bunck, Mathijs C., Stefanski, Adam

“…In this randomized trial, adults with obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1…”
Get full text

Efficacy and safety of semaglutide for weight management: evidence from the STEP program by Amaro, Anastassia, Sugimoto, Danny, Wharton, Sean

“…Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease associated with various health complications and increased…”
Get full text

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity by Wharton, Sean, Blevins, Thomas, Connery, Lisa, Rosenstock, Julio, Raha, Sohini, Liu, Rong, Ma, Xiaosu, Mather, Kieren J., Haupt, Axel, Robins, Deborah, Pratt, Edward, Kazda, Christof, Konig, Manige

“…In this 36-week, randomized trial, daily oral orforglipron was associated with weight reduction, with efficacy and safety similar to those of injectable GLP-1…”
Get full text